Hydroxychloroquine Shortage Update: What Patients Need to Know in 2026

If you've searched "hydroxychloroquine shortage 2026" and landed here, you're looking for a straight answer. Here it is: as of early 2026, there is no active FDA-declared national shortage of hydroxychloroquine. The major shortage that disrupted supply in 2020 has been resolved. However, individual pharmacy stockouts still occur, and patients with lupus and rheumatoid arthritis should stay informed about how to protect their medication access.

Current Status: Is Hydroxychloroquine in Shortage in 2026?

No active national shortage. The FDA's drug shortage database does not list hydroxychloroquine as currently in shortage. Generic hydroxychloroquine sulfate is manufactured by multiple companies including Dr. Reddy's, Mylan (Viatris), Amneal, Zydus, and others. This multi-manufacturer landscape provides resilience against a single company's supply disruption.

That said, localized stockouts do happen. Certain pharmacies — especially smaller independents or those in rural areas — may experience temporary gaps. Patients should not interpret a single pharmacy being out of stock as a national shortage.

The 2020 Hydroxychloroquine Shortage: A Timeline

Understanding what happened in 2020 helps patients understand why this drug has such a complicated reputation for availability. Here's how it unfolded:

• March 19, 2020: Hydroxychloroquine was promoted as a potential COVID-19 treatment in a widely publicized White House briefing. Demand spiked immediately.
• March 28, 2020: The FDA issued an Emergency Use Authorization (EUA) for hydroxychloroquine in hospitalized COVID-19 patients.
• March 31, 2020: The FDA formally recognized shortages of hydroxychloroquine and chloroquine, citing "a significant surge in demand."
• April 2020: Novartis pledged up to 130 million doses to help ease the shortage. Several states enacted emergency dispensing rules to protect lupus and RA patients.
• June 2020: The FDA revoked the EUA for COVID-19 after clinical trials showed it provided no significant benefit against the virus.
• Late 2020 onward: Demand from COVID-19 use collapsed, supply normalized, and the shortage gradually resolved.

Impact on Lupus and Rheumatoid Arthritis Patients

The 2020 shortage had a measurable impact on real patients. Research published in peer-reviewed journals showed that patients with rheumatic diseases across Africa, Southeast Asia, the Americas, and Europe had difficulty filling hydroxychloroquine prescriptions during the peak COVID-19 period. Those who couldn't access their medication experienced higher disease activity and worse physical and mental health outcomes.

This experience underscored a critical point: for lupus patients especially, hydroxychloroquine is not just a convenience — it is a disease-modifying treatment that prevents organ damage, reduces flare frequency, and improves long-term survival outcomes.

Why Some Pharmacies Still Run Out in 2026

Even without a national shortage, individual pharmacies can run out due to:

• Manufacturer-specific back orders (e.g., one manufacturer's 500-count bottles on back order while others remain available)
• Inconsistent pharmacy ordering patterns
• Regional demand spikes at the start of each year when insurance plans reset
• Global supply chain disruptions affecting raw material sources

What Patients Should Do Right Now

Given the 2020 experience, here's how patients can protect themselves from future supply disruptions:

1. Switch to a 90-day supply. A 90-day prescription provides a meaningful buffer against temporary stockouts and is often available at a lower per-dose cost through mail-order pharmacies.
2. Know your alternatives. Talk to your rheumatologist about what you should do if hydroxychloroquine becomes unavailable for more than a week or two.
3. Know which pharmacies carry it locally. Identify 2-3 pharmacies near you that reliably stock hydroxychloroquine so you have a backup if your usual pharmacy is out.
4. Keep your rheumatologist informed. If you experience any supply gap, contact your provider immediately rather than simply going without.

Current Availability Summary

Shortage status: No active national shortage (2026)

Generic availability: Multiple manufacturers — generally available

Cash price: As low as $15–$20 with GoodRx or SingleCare coupons for a 30-day supply of generic (200 mg)

Insurance coverage: Widely covered; generic is typically Tier 1–2 on most plans

If you're having trouble finding hydroxychloroquine at your local pharmacy, see our guide on how to find hydroxychloroquine in stock near you, or use medfinder to have pharmacies in your area checked on your behalf.